aa-logo-rgba-no-text-square.png

Africa: Covax Plan Boosts Covid-19 Vaccine Hopes for Developing Countries

Without a magic wand, no country will immediately be able to vaccinate very large numbers of people, but for developing countries, the hurdles between approval in the northern hemisphere and a jab in the arm in the ‘global south’ are infinitely more challenging.

On the heels of extraordinarily successful results announced by four Covid-19 vaccine developers within three weeks of one another, the question of whether developing countries will be “left behind” continues to be asked.

COVAX, a massively funded global collaboration involving 187 countries, aims to ensure that they are not, helping 92 of the least advanced countries to buy and roll out a vaccine for the most vulnerable 20% of their populations – although only about 3% of all countries’ populations will receive vaccines through COVAX early in 2021.

The past few weeks have seen astonishingly uplifting news about Covid-19 vaccines: Global pharmaceutical giants Pfizer/BioNTech, Moderna, and AstraZeneca all announced better-than-expected effectiveness of three vaccines from large-scale clinical trials (two above 90%, one at 70%), making the longstanding promise of vanquishing coronavirus a reality. (A fourth, Sputnik, from Russia’s Gamaleya research institute, also announced 95% efficacy but the lack of available data on its clinical trials has cast…


Source link

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Leave a Reply